Literature DB >> 6831050

Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro.

W T Gerson, D G Fine, S P Spielberg, L L Sensenbrenner.   

Abstract

A 53-yr-old man sequentially developed aplastic anemia from phenytoin and carbamazepine. Both compounds undergo metabolism to potentially toxic arene oxide intermediates. We tested the hypothesis that the patient's adverse reactions were due to a defect in detoxification of such metabolites by challenging his peripheral lymphocytes with drug metabolites generated by a murine hepatic microsomal system in vitro. The patient's cell viability was normal in the absence of drugs. However, his cells showed greater toxicity from both phenytoin and carbamazepine metabolites than did controls. Toxicity was dependent on microsomes and NADPH. Intermediate toxicity was noted in cells from the patient's mother. The results provide the first evidence for a role of arene oxide drug metabolites in aplastic anemia in humans and suggest that enhanced susceptibility to toxicity may be based on an inherited abnormality in metabolite detoxification.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831050

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Idiosyncratic drug reactions: a mechanistic evaluation of risk factors.

Authors:  B K Park; M Pirmohamed; N R Kitteringham
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

2.  Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro.

Authors:  R J Riley; N R Kitteringham; B K Park
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

Review 3.  Anticonvulsant hypersensitivity syndrome in children: incidence, prevention and management.

Authors:  Alberto Verrotti; Daniela Trotta; Carmela Salladini; Francesco Chiarelli
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 4.  Clinical features and management of poisoning due to phenytoin.

Authors:  J R Larsen; L S Larsen
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

5.  Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. 5-7 April 1989, Bristol. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

6.  Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk.

Authors:  N H Shear; S P Spielberg
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

Review 7.  Anticonvulsant drugs and hematological disease.

Authors:  A Verrotti; A Scaparrotta; S Grosso; F Chiarelli; G Coppola
Journal:  Neurol Sci       Date:  2014-03-12       Impact factor: 3.307

8.  Apparently normal phenytoin metabolism in a patient with phenytoin-induced rash and lymphadenopathy.

Authors:  J H Maguire; G Wettrell; A Rane
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

9.  Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine.

Authors:  M Pirmohamed; A Graham; P Roberts; D Smith; D Chadwick; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

Review 10.  Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients.

Authors:  Emmanuel Andrès; Esther Noel; Jean-Emmanuel Kurtz; Nourredine Henoun Loukili; Georges Kaltenbach; Frédéric Maloisel
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.